A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study
Our novel classification revealed that PARPi efficacy and prognosis varied significantly by mutation location, with the central region linked to superior outcomes compared with the N- and C-terminal regions. Comprehensive mutation profiling should guide treatment decisions to optimize outcomes in patients with BRCA-mutated ovarian cancer.
Authors
- H. Guo
- L. Tao
- Y. Z. Zhang
- Y. Jin
- D. Zhao
- X. Huang
- J. Song
- W. Kong
- Q. Liu
- C. Huang
- Y. Fan
- C. Ha
- Y. Li
- S. Wang
- J. Qiao
- X. Yang
- M. Wu
- Z. Cui
- Y. L. Liu
Institutions
- Qingdao University (CN)
- Hebei Medical University (CN)
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Kunming Medical University (CN)
- Second Hospital of Hebei Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Ningxia Medical University (CN)
- Peking University First Hospital (CN)
- Ningxia Medical University General Hospital (CN)
- Peking University Third Hospital (CN)
- Beijing Obstetrics and Gynecology Hospital (CN)
- Inner Mongolia Medical University (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106060
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00